Forensic Analysis · Medical Devices · as of Nov 11, 2026
Orthopediatrics Corp (KIDS)
A forensic read on Orthopediatrics Corp built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
2.7
Distress distance
Clean
Earnings quality
3
Forensic signals
-11.3%
ROE
15.4%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Orthopediatrics Corp earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 2.7, placing it in the Safe zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-7.4%
FY2025
Return on invested capital.Return on invested capital is -7.4% in the latest fiscal year and slipping across FY2023–FY2025 from -5.8%. After-tax operating profit was ($21M) in FY2023 and ($31M) in FY2025, with operating income at -18.0% of revenue in FY2023, -17.1% in FY2024 and -16.6% in FY2025. The capital base behind it grew +15% across FY2023–FY2025, from $366M to $421M, while the return fell 1.6 points, so the dollars added over that window earned less than the -5.8% the older base was already earning. FY2025's operating profit carried a $6M restructuring charge and a $2M goodwill write-off that alone took about 1.4 points off that year's return, so about 1.4 of the 1.6-point fall across FY2023–FY2025 is that charge landing in the latest year rather than the capital earning less. A non-cash write-down lowers the reported return in the year it lands.
83d DSO
FY2024→FY2025
Receivables vs revenue.Days sales outstanding moved from 76 to 83 days FY2024→FY2025 (receivables +27% vs revenue +15%). Receivables are creeping up relative to sales. Across FY2023–FY2025 the day count ran 85 → 76 → 83 days, so the latest reading sits on top of a record that was flat or falling before it — one year's move, not a direction the business has been travelling in. Both figures are measured on period-end balances rather than the beginning-plus-ending average, because averaging needs the balance a year before every reading — FY2024's opening balance is on file, but across the 3 fiscal years read here (FY2023–FY2025) the average yields only 2 day counts (1 step), too few to tell a climb from one year's move.DSO (days sales outstanding): the average days the company waits to collect cash after a sale.
$2M
FY2025
Goodwill impairments.Took $2M of goodwill writedowns across 1 year (FY2025 ($2M)). Writedowns mean past acquisitions underperformed what was paid for them.
Key fundamentals
Latest Revenue$236.3M
Revenue Growth YoY+15.4%
Revenue CAGR (2yr)+26.1%
Net Margin-16.8%
Free Cash Flow-$16.0M
Return on Equity-11.3%
Debt / Equity0.29x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Orthopediatrics Corp's actual 10-K/10-Q/8-K filings?